Literature DB >> 18507487

Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment?

Christoph U Correll1.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18507487     DOI： 10.4088/jcp.v69n0422

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  9 in total

Review 1.  Is rational antipsychotic polytherapy feasible? A selective review.

Authors:  Rune Andreas Kroken; Erik Johnsen
Journal:  Curr Psychiatry Rep       Date:  2012-06       Impact factor: 5.285

2.  Trends in adult antipsychotic polypharmacy: progress and challenges in Florida's Medicaid program.

Authors:  Robert J Constantine; Ross Andel; Rajiv Tandon
Journal:  Community Ment Health J       Date:  2010-01-23

3.  Treatment of schizoaffective disorder.

Authors:  Elisa Cascade; Amir H Kalali; Peter Buckley
Journal:  Psychiatry (Edgmont)       Date:  2009-03

4.  Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior.

Authors:  Christoph U Correll; Ladan Shaikh; Juan A Gallego; Jeffrey Nachbar; Vladimir Olshanskiy; Taishiro Kishimoto; John M Kane
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 5.  Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Authors:  Christoph U Correll; Juan A Gallego
Journal:  Psychiatr Clin North Am       Date:  2012-07-24

6.  Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Jennifer A Flynn; Yuka Tanji; Michihiro Takahashi
Journal:  Clinicoecon Outcomes Res       Date:  2012-01-13

7.  Comparison of patients undergoing switching versus augmentation of antipsychotic medications during treatment for schizophrenia.

Authors:  Haya Ascher-Svanum; Alan Jm Brnabic; Anthony H Lawson; Bruce J Kinon; Virginia L Stauffer; Peter D Feldman; Katarina Kelin
Journal:  Neuropsychiatr Dis Treat       Date:  2012-03-15       Impact factor: 2.570

8.  Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.

Authors:  Wenyu Ye; Haya Ascher-Svanum; Yuka Tanji; Jennifer A Flynn; Michihiro Takahashi; Robert R Conley
Journal:  Neuropsychiatr Dis Treat       Date:  2012-06-18       Impact factor: 2.570

9.  Study protocol: safety correction of high dose antipsychotic polypharmacy in Japan.

Authors:  Tsuruhei Sukegawa; Ataru Inagaki; Yoshio Yamanouchi; Toshiya Inada; Takashi Yoshio; Reiji Yoshimura; Nakao Iwata
Journal:  BMC Psychiatry       Date:  2014-04-07       Impact factor: 3.630
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.